Azathioprine immunosuppression and disease modification in Parkinson's disease (AZA-PD): a randomised double-blind placebo-controlled phase II trial protocol.
MetadataShow full item record
Greenland, J., Cutting, E., Kadyan, S., Bond, S., Chhabra, A., & Williams-Gray, C. (2020). Azathioprine immunosuppression and disease modification in Parkinson's disease (AZA-PD): a randomised double-blind placebo-controlled phase II trial protocol.. BMJ open, 10 (11), e040527. https://doi.org/10.1136/bmjopen-2020-040527
The immune system is implicated in the aetiology and progression of Parkinson’s disease (PD). Inflammation and immune activation occur both in the brain and in the periphery, and a pro-inflammatory cytokine profile is associated with more rapid clinical progression. Furthermore, the risk of developing PD is related to genetic variation in immune-related genes, and reduced by the use of immunosuppressant medication. We are therefore conducting a ‘proof of concept’ trial of azathioprine, an immunosuppressant medication, to investigate whether suppressing the peripheral immune system has a disease-modifying effect in PD.
This trial is funded by Cambridge Centre for Parkinson-Plus (grant no: RG95450) and the Cure Parkinson’s Trust (grant ref CW011), and supported by the NIHR Cambridge Biomedical Research Centre (grant ref no 146281). CHWG is supported by a RCUK/UKRI Research Innovation Fellowship awarded by the Medical Research Council (MR/R007446/1).
Cambridge University Hospitals NHS Foundation Trust (CUH) (146281)
Embargo Lift Date
External DOI: https://doi.org/10.1136/bmjopen-2020-040527
This record's URL: https://www.repository.cam.ac.uk/handle/1810/311534
All rights reserved